Abstract
Trillium govanianum was investigated for its potential anti‐lung cancer activity against Non‐small cell lung cancer (NSCLC) using an integrated metabolomic, computational, and experimental approach. Ultra‐performance liquid chromatography coupled with electrospray ionization‐mass spectrometry (UPLC‐ESI‐MS) profiling of petroleum ether (PE), hexane (Hex), ethyl acetate (EtOAc), and methanol (MeOH) extracts putatively annotated bioactive metabolites, including Diosgenin, Pennogenin E, Govanoside A, Trillarin, Polyphyllin VII, and Sarsasapogenin. Network pharmacology analysis integrated NSCLC associated targets from multiple databases with predicted metabolite targets, revealing 374 overlapping targets associated with NSCLC. Protein‐protein interaction analysis identified EGFR, SRC, VEGFA , and STAT3 as major hub proteins involved in cancer progression. Molecular docking studies demonstrated strong binding affinities of the metabolites toward these targets, with Govanoside A showing the highest affinity for EGFR (−11.3 kcal/mol) through multiple hydrogen bond interactions. In vitro cytotoxicity testing on A‐549 lung cancer cells showed that the MeOH extract exhibited the strongest anticancer activity, reducing cell viability to approximately 35% at 500 µg/mL. Furthermore, all metabolites displayed favorable, ADMET characteristics and satisfied Lipinski's Rule of Five. Overall, these findings suggest that T. govanianum possesses promising multi‐target therapeutic potential against NSCLC, potentially through the modulation of the EGFR, SRC, VEGFA , and STAT3 signaling pathways.

This publication has 83 references indexed in Scilit: